Cend Therapeutics Announces First Patient Dosing in Clinical Trial of CEND-1 for the Treatment of Selected Gastrointestinal Cancers

NEXT STORY
Codiak Reports Positive Initial Data for exoSTING™ Phase 1/2 Trial Indicating Tolerability, Immune Activation, and Evidence of Tumor Shrinkage in Injected and Non-Injected Tumors in the First Three Dose Escalation Cohorts
PREV STORY
NRx Pharmaceuticals Reports Third-Quarter 2021 Business Update and Financial Results
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Ascendis Pharma A/S Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ hGH (Lonapegsomatropin) for Pediatric Growth Hormone Deficiency

author_avatar
NASDAQ Market News

Molecular Diagnostics Market is expected to reach US$18.9 bn with a CAGR of around 11.6% from 2016 to 2025; TMR

Molecular Diagnostics to Gain Momentum with Prevailing Number of InfectionsAlbany, New York, Dec. 06, ...

author_avatar
NASDAQ Market News

Allecra Therapeutics Announces Positive Top-Line Results for Phase 3 ALLIUM Clinical Trial of EXBLIFEP® for Complicated Urinary Tract Infections

author_avatar
NASDAQ Market News